Anti-HER2 scFv antibody-directed lentiviral delivery of myrosinase for eradicating HER2+cancer cells after dosing prodrug sinigrin

被引：0
|
作者：
Tarar, Ammar Ahmad [1 ]
Peng, Ching-An [1 ]
机构：
[1] Univ Idaho, Moscow, ID 83843 USA
来源：
CANCER RESEARCH | 2022年 / 82卷 / 12期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3291
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Administration of anti-HER2 antibody after nonmyeloablative allogeneic stem cell transplantation in metastatic breast cancer
    G L Banna
    S M L Aversa
    G Crivellari
    C Ghiotto
    V Chiarion-Sileni
    S Monfardini
    British Journal of Cancer, 2006, 94 : 1550 - 1552
  • [42] Administration of anti-HER2 antibody after nonmyeloablative allogeneic stem cell transplantation in metastatic breast cancer
    Banna, G. L.
    Aversa, S. M. L.
    Crivellari, G.
    Ghiotto, C.
    Chiarion-Sileni, V.
    Monfardini, S.
    BRITISH JOURNAL OF CANCER, 2006, 94 (10) : 1550 - 1552
  • [43] Long-term responders to single-agent margetuximab, an Fc-modified anti-HER2 monoclonal antibody, in metastatic HER2+breast cancer patients with prior anti-HER2 therapy
    Im, S-A
    Bang, Y-J
    Oh, D-Y
    Giaccone, G.
    Bauer, T.
    Nordstrom, J.
    Li, H.
    Moore, P.
    Hong, S.
    Baughman, J.
    Rock, E.
    Burris, H.
    CANCER RESEARCH, 2019, 79 (04)
  • [44] Enhanced gene delivery to HER-2-overexpressing breast cancer cells by modified immunolipoplexes conjugated with the anti-HER-2 antibody
    Lee, CH
    Hsiao, M
    Tseng, YL
    Chang, FH
    JOURNAL OF BIOMEDICAL SCIENCE, 2003, 10 (03) : 337 - 344
  • [45] In vitro assessment of the effects of anti-HER2 monoclonal antibodies on proliferation of HER2-overexpressing breast cancer cells
    Tahmasebi, Fathollah
    Kazemi, Tohid
    Amiri, Mohammad Mehdi
    Khoshnoodi, Jalal
    Mahmoudian, Jafar
    Bayat, Ali Ahmad
    Jeddi-Tehrani, Mahmood
    Rabbani, Hodjatallah
    Shokri, Fazel
    IMMUNOTHERAPY, 2014, 6 (01) : 43 - 49
  • [46] Anti-HER2 single domain antibody-conjugated dendrimers for targeted delivery of truncated-Bid transgene to breast cancer cells
    Sofla, Farnoush Jafari Iri
    Rahbarizadeh, Fatemeh
    Ahmadvand, Davoud
    Nomani, Alireza
    Vernet, Erik
    JOURNAL OF BIOACTIVE AND COMPATIBLE POLYMERS, 2019, 34 (01) : 39 - 57
  • [47] HER2 status of circulating tumor cells in HER2-positive metastatic breast cancer patients: A valuable biomarker in anti-HER2 therapy
    Jiang, Z.
    Li, L.
    Liu, Y.
    Wang, T.
    Zhang, S.
    Yuan, Y.
    Bian, L.
    Liu, Q.
    Qi, F.
    CANCER RESEARCH, 2013, 73
  • [48] Therapeutic potential of an anti-HER2 single chain antibody-DM1 conjugates for the treatment of HER2-positive cancer
    Zhang, Hang
    Wang, Yuxi
    Wu, Yangping
    Jiang, Xiaohua
    Tao, Yiran
    Yao, Yuqin
    Peng, Yujia
    Chen, Xiangzheng
    Fu, Yuyin
    Yu, Lin
    Wang, Ruixue
    Lai, Qinhuai
    Lai, Weirong
    Li, Wenting
    Kang, Yuhuan
    Yi, Shuli
    Lu, Ying
    Gou, Lantu
    Wu, Min
    Yang, Jinliang
    SIGNAL TRANSDUCTION AND TARGETED THERAPY, 2017, 2
  • [49] Anti-HER2/neu-antibody binding profile in patients with breast-cancer
    Jasinska, J
    Zeillinger, R
    Hoffmann-Sommergruber, K
    Scheiner, O
    Wiltschke, C
    Zielinski, CC
    EUROPEAN JOURNAL OF CANCER, 1998, 34 : S5 - S5
  • [50] Population pharmacokinetics of zanidatamab, an anti-HER2 biparatopic antibody, in patients with advanced or metastatic cancer
    Jeffrey R. Proctor
    Elaina M. Gartner
    Todd E. Gray
    Rupert H. Davies
    Cancer Chemotherapy and Pharmacology, 2022, 90 : 399 - 408
12345